Table 3 Effect of JIA disease activity and glucocorticoid use over sex hormones
From: Endocrine dysfunction in patients with juvenile idiopathic arthritis
Variables | Categories | Testosterone for age | p-value | Estradiol for age | p-value | ||
|---|---|---|---|---|---|---|---|
Low (N = 34) | Normal (N = 38) | Low (N = 11) | Normal (N = 24) | ||||
N (%) | N (%) | N (%) | N (%) | ||||
Growth velocity | Normal | 22 (71) | 25 (73.5) | 0.818 | 8 (88.9) | 16 (76.2) | 0.426 |
Slow | 9 (29) | 9 (26.5) | 1 (11.1) | 5 (23.8) | |||
Disease duration | < 24 months | 10 (29.4) | 15 (39.5) | 0.370 | 7 (63.6) | 6 (25) | 0.057 |
>=24 months | 24 (70.6) | 23 (60.5) | 4 (36.4) | 18 (75) | |||
Current GC use | Yes | 25 (73.5) | 25 (65.8) | 0.476 | 8 (72.7) | 19 (79.2) | 0.674 |
No | 9 (26.5) | 13 (34.2) | 3 (27.3) | 5 (20.8) | |||
Duration of GC use | < 3 months | 25 (73.5) | 27 (71.1) | 0.868 | 5 (45.5) | 19 (79.2) | 0.046* |
>=3 months | 9 (26.5) | 11 (28.9) | 6 (54.5) | 5 (14.3) | |||
Cumulative GC dose | < 1100 mg | 28 (82.4) | 31 (81.6) | 0.932 | 8 (72.7) | 22 (91.7) | 0.137 |
>=1100Â mg | 6 (17.6) | 7 (18.4) | 3 (27.3) | 2 (8.3) | |||
JADAS27 | High + Moderate | 31 (85.9) | 34 (89.5) | 0.807 | 7 (63.6) | 20 (83.3) | 0.226 |
Low + Inactive | 3 (14.1) | 4 (10.5) | 4 (36.4) | 4 (16.7) | |||